gms | German Medical Science

65. Jahrestagung der Deutschen Gesellschaft für Neurochirurgie (DGNC)

Deutsche Gesellschaft für Neurochirurgie (DGNC) e. V.

11. - 14. Mai 2014, Dresden

Brain metastases from NSCLC: A mono-institutional restrospective analysis

Meeting Abstract

  • Frederik Enders - Klinik für Neurochirurgie, Universitätsklinikum Heidelberg, Heidelberg, Deutschland
  • Andreas von Deimling - Klinik für Neuropathologie, Institut für Pathologie, Ruprecht-Karls-Universität Heidelberg
  • Christel Herold-Mende - Klinik für Neurochirurgie, Universitätsklinikum Heidelberg, Heidelberg, Deutschland
  • Andreas Unterberg - Klinik für Neurochirurgie, Universitätsklinikum Heidelberg, Heidelberg, Deutschland

Deutsche Gesellschaft für Neurochirurgie. 65. Jahrestagung der Deutschen Gesellschaft für Neurochirurgie (DGNC). Dresden, 11.-14.05.2014. Düsseldorf: German Medical Science GMS Publishing House; 2014. DocMI.17.07

doi: 10.3205/14dgnc375, urn:nbn:de:0183-14dgnc3751

Veröffentlicht: 13. Mai 2014

© 2014 Enders et al.
Dieser Artikel ist ein Open Access-Artikel und steht unter den Creative Commons Lizenzbedingungen (http://creativecommons.org/licenses/by-nc-nd/3.0/deed.de). Er darf vervielfältigt, verbreitet und öffentlich zugänglich gemacht werden, vorausgesetzt dass Autor und Quelle genannt werden.


Gliederung

Text

Objective: Brain metastases are the most common malignant brain tumors in adults. Among different malignant primaries, brain metastases are most frequently associated with lung cancer. Treatment options are microsurgery, radiotherapy and chemotherapy. However, the prognosis for patients with brain metastasis remains poor. Therefore we performed an in-depth analysis of these patients with regard to their clinical outcome to identify prognostic factors.

Method: A cohort of 134 patients with brain metastases from non-small-cell lung cancer (NSCLC), who had undergone surgery at our department between 2002 and 2013 was analyzed. Age, gender, type of treatment, presence of neurologic symptoms, Karnofsky performance status (KPS), smoking history, presence and localization of extracranial metastasis, number, localization and size of brain metastases and percentage of Ki67 positive cells were assessed and survival analysis was performed by using Kaplan-Meier method.

Results: Mean age was 61.8 years. 24 of 134 patients are still alive. Median overall survival time (OST) was 9.9 months. Statistically significant prognostic factors for the OST included the existence of extracranial metastases, postoperative whole brain radiation therapy (WBRT) and Ki67 positive cells of less than 60%. Patients, who had been diagnosed with brain metastases before the onset of neurologic symptoms also had a better OST (20.8 vs. 9.4 months, p<0.05). A KPS >70% was also associated with a better OST (5.7 vs. 11.8 months) although not significant (p: 0.25). Age, gender, the size and the number of intracranial metastases did not have significant impact on the OST. Five of 134 patients turned out to be long-term survivors (56.6 -75.1 months).

Conclusions: In the present study extracranial metastases, postoperative WBRT and the presentation of neurologic symptoms at diagnosis of brain metastases were the most important prognostic factors in NSCLC-patients suffering from brain metastases. Therefore early surgical treatment and postoperative WBRT might be important options to improve the overall survival time.